Last reviewed · How we verify
PEG-IFN-SA /RBV
PEG-IFN-SA is a pegylated interferon-alpha combined with ribavirin to stimulate antiviral immune responses and inhibit viral replication.
PEG-IFN-SA is a pegylated interferon-alpha combined with ribavirin to stimulate antiviral immune responses and inhibit viral replication. Used for Chronic hepatitis C virus (HCV) infection.
At a glance
| Generic name | PEG-IFN-SA /RBV |
|---|---|
| Sponsor | Beijing Kawin Technology Share-Holding Co., Ltd. |
| Drug class | Pegylated interferon-alpha with nucleoside analog |
| Target | Interferon-alpha receptor; viral RNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Virology/Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Pegylated interferon-alpha (PEG-IFN-SA) enhances the half-life and immunogenicity of interferon-alpha, which activates natural killer cells and macrophages to combat viral infections. Ribavirin (RBV) is a nucleoside analog that inhibits viral RNA synthesis. Together, they work synergistically to suppress viral replication and promote immune clearance of infected cells.
Approved indications
- Chronic hepatitis C virus (HCV) infection
Common side effects
- Flu-like symptoms (fever, fatigue, myalgia)
- Hematologic toxicity (anemia, thrombocytopenia, leukopenia)
- Psychiatric effects (depression, anxiety)
- Thyroid dysfunction
- Injection site reactions
- Teratogenicity (ribavirin)
Key clinical trials
- Safety Study of Recombinant Interferon Variant(PEG-IFN-SA) to Treat HCV Disease (PHASE1, PHASE2)
- Efficacy and Safety Study of PEG-IFN-SA and Ribavirin to Treat Chronic Hepatitis C (PHASE3)
- A Phase Ⅱ Dose-escalating Study of PEG-IFN-SA and Ribavirin in IFN Naive Patients With Chronic Hepatitis C (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |